Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
De novo and acquired resistance to platinum therapy such as cisplatin (CDDP) is a clinical challenge in gastric cancer treatment. Aberrant expression and activation of aurora kinase A (AURKA) and eukaryotic translation initiation factor 4E (eIF4E) are detected in several cancer types. Herein, we investigated the role of AURKA in CDDP resistance in...
Alternative Titles
Full title
Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537695
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5537695
Other Identifiers
ISSN
1574-7891
E-ISSN
1878-0261
DOI
10.1002/1878-0261.12066
